Wegovy
semaglutide
Compare FDA-approved weight-loss medications, check BMI eligibility, and verify telehealth clinics.
Search 162 GLP-1-related FDA warning letters and 2,273 NPPES records with an obesity medicine taxonomy across 50 states, DC and Puerto Rico from public federal records.

Filter by weekly injection, daily oral tablet, or active ingredient. Direct facts from FDA-approved labels.
semaglutide
tirzepatide
oral semaglutide
orforglipron
liraglutide
Check whether your Body Mass Index (BMI) matches FDA label criteria for chronic weight management medications.
Obesity (BMI ≥ 30.0)
Based on official FDA prescribing information (BMI ≥30, or BMI ≥27 with comorbidity), this matches labeled indication criteria for weight management GLP-1 medications.
Current weight is ~42 lbs above the standard normal BMI threshold.
Educational Notice: Calculated instantly in your browser; no personal health information is stored or transmitted. This screening tool is based on official FDA medication labels for chronic weight management and is for educational reference only, not medical diagnosis or advice. Only a licensed healthcare provider can evaluate your medical history and determine appropriate treatment.
Calculate estimated out-of-pocket costs with manufacturer savings cards, and generate your personal clinical discussion sheet.
Estimate your realistic out-of-pocket monthly expense and determine manufacturer copay card eligibility rules.
Selected: Zepbound (Tirzepatide weekly injection). List price before insurance or coupons: ~$1,060 / 28-day supply.
Your commercial insurance plan covers anti-obesity medications on its formulary.
PA requirement notes: Approval typically requires documented BMI ≥30 or BMI ≥27 with at least one metabolic comorbidity, plus notes on prior lifestyle intervention attempts.
Transparency & Compliance Notice: Out-of-pocket estimates are educational benchmarks reflecting published manufacturer coupon guidelines, wholesale acquisition cost benchmarks, and commercial health plan rules as of 2026. TrimSoMo is an independent, non-commercial informational directory and has no financial affiliation with Novo Nordisk, Eli Lilly, or pharmacy benefit managers (PBMs). Final copays are determined solely by your employer contract, insurer deductible, and dispensing pharmacy.
Recent GLP-1 warning letters FDA sent to telehealth companies, online sellers, compounders, and pharmacies.
FDA says the company's website and X posts made false or misleading claims that its compounded semaglutide and tirzepatide were FDA-approved, well-studied, American made, and farm-to-table, and that product labels suggested RonanRx was the compounder of those drugs "when in fact it is not."
FDA found www.cheapmedicineshop.com introducing unapproved and misbranded injectable semaglutide ("Semanext Injection") into interstate commerce without an approved application or adequate directions for use.
FDA says the website introduced unapproved and misbranded injectable semaglutide (Semanat Injection) into interstate commerce without FDA approval, adequate directions, or required prescription, violating FD&C Act sections 301, 502(f)(1), 503(b)(1), and 505(a).
FDA says the firm compounded semaglutide and tirzepatide products that "appear to be essentially copies" of FDA-approved drugs regularly and in inordinate amounts without valid individualized prescriber determinations, and prepared sterile products under insanitary conditions with significant CGMP violations.
FDA's July 2026 review of texpeptide.com found seven products, including semaglutide, tirzepatide, and retatrutide, to be unapproved new drugs offered without approved applications, violating FD&C Act sections 301(d) and 505(a).
Doctors and clinics listed with an obesity medicine specialty in the CMS NPI Registry. Specialty is self-reported, not a board certification.
Common questions about dosing options, BMI qualifications, and stopping medications.
The FDA has approved five GLP-1 receptor agonist medications for chronic weight management in adults with obesity or overweight: Wegovy (semaglutide injection), Zepbound (tirzepatide injection), Wegovy Tablets (oral semaglutide), Foundayo (oral orforglipron), and Saxenda (liraglutide injection). They are indicated alongside a reduced-calorie diet and increased physical activity.
Plain-English articles on stopping GLP-1s, BMI criteria, and compounded medications.
What to discuss with your clinician before stopping a GLP-1 medication.
A summary of the FDA’s current statements on compounded GLP-1 medications, with links to the FDA pages.
For weight reduction in adults, the FDA labels describe BMI ≥30, or BMI ≥27 with at least one weight-related comorbid condition.
How telehealth programs work:1. Read about medications2. Online clinician assessment3. Pharmacy fulfillment.
Learn how programs work